IMR Press / FBL / Volume 12 / Issue 8 / DOI: 10.2741/2297

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

An insight into the pathophysiology of thrombosis in antiphospholipid syndrome
Show Less
1 Department of Clinical Biochemistry and Immunohematology, Cardiovascular Risk Factor Disease Research Program, Faculty of Health Sciences, Universidad de Talca, Chile
2 Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile
3 School of Medicine, Faculty of Health Sciences, Universidad Catolica del Maule, Talca, Chile
4 Department of Hematology, Universidad Favaloro, Buenos Aires, Argentina
Academic Editor:Vicente Andres
Front. Biosci. (Landmark Ed) 2007, 12(8), 3093–3103;
Published: 1 May 2007

The antiphospholipid syndrome (APS) is a disorder which is characterized by the presence of autoimmune antiphospholipid antibodies (APL) and increased risk of thrombosis and fetal loss. APL are associated with recurrent abortions in APS patients and participate in the pathogenesis of venous or arterial thrombosis, although the underlying mechanisms are poorly understood. Antigens that are targeted by APL include beta 2 glycoprotein I and prothrombin. Pathological mechanisms of APL encompass inhibition of natural anticoagulants (protein C system, tissue factor pathway inhibitor, and annexin A5), inhibition of the fibrinolytic system, activation of endothelial cells, monocytes and platelets, and complement activation. In this review, we discuss the main targets of APL and prothrombogenic mechanisms of APL.

Back to top